Fresenius Kabi Limited

Business Development Manager

Job Locations UK-City of London-Central London
Posted Date 2 months ago(04/03/2024 11:02)
Job ID
2024-1727
# of Openings
1
Category
Sales

Overview

The Company

Fresenius Kabi is a global healthcare company that specialises in lifesaving medicines and technologies. Our product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies, biosimilars and clinical nutrition products as well as the medical devices for administering these products.

The Fresenius Group employs over 300,000 high-calibre professionals across the world, with a workforce of circa. 1,000 across the UK and Ireland.

 

Overview of Role

We are looking for a Business Development Manager in the London and South-East area.

This position reports in to the National Sales Manager (NSM) within the Parenteral Nutrition (PN) team and will be an integral part of a multi-disciplinary sales team.

The main focus of the role will be the promotion and profitable sales of the Fresenius Kabi Parenteral Nutrition (PN) product range and supporting services.

Responsibilities

• Promotion of the PN portfolio to key customers in the secondary care setting with the aim to exceed sales versus target for promotional priorities
• Develop and implement business plans and strategies for both Fresenius Kabi and competitor key accounts
• Work with NSM and marketing to develop successful sales strategies in your designated key accounts
• Attend seminars, exhibitions or meetings as directed by the NSM
• Maintain a high level of knowledge of customers, accounts, services, changes within the PN market and all relevant clinical developments

Qualifications

• Life science degree or equivalent (desirable, not essential)
• Clinical/technical background in pharmaceutical/healthcare sales or the NHS
• ABPI accreditation (desirable, not essential)
• Demonstrate good business acumen
• Team player
• Excellent communication and interpersonal skills

Options

Sorry the Share function is not working properly at this moment. Please refresh the page and try again later.
Share on your newsfeed